Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys

L. A. Edwards, L. C. Read, S. J. Nishio, A. J. Weir, W. Hull, S. Barry, Dennis M Styne, J. A. Whitsett, Alice F Tarantal, C. George-Nascimento, Charles Plopper

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

To compare the effects of epidermal growth factor (EGF) and betamethasone on the morphogenesis of the gas exchange region and the differentiation of the alveolar type II cell during fetal lung development, fetal rhesus monkeys (78% gestation) were treated in utero with EGF (5.33 mg/kg total dose), betamethasone (2.6 mg/kg total dose) or the carrier, saline (control), every other day for 7 days. EGF-treated monkeys had significantly increased body and adrenal weights. Betamethasone-treated monkeys had significantly decreased body and adrenal weights. Exogenous EGF reduced cytoplasmic glycogen and increased the cytoplasmic organelle and SP-A content within alveolar type II cells. In contrast, exogenous betamethasone did not alter alveolar type II cell cytodifferentiation. Neither EGF nor betamethasone treatment significantly altered the structure of the gas exchange region as shown by a lack of change from controls in alveolar airspace size or in the fraction of the gas exchange region that was potential airspace. We conclude that at clinically relevant doses, EGF greatly accelerates the maturation of alveolar type II cells, whereas betamethasone does not. Exogenous EGF may act directly on alveolar type II cells because these cells contain EGF receptor. Neither EGF nor betamethasone had dramatic effects on the morphogenesis of the gas exchange region.

Original languageEnglish (US)
Pages (from-to)1025-1032
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume274
Issue number2
StatePublished - 1995

Fingerprint

Alveolar Epithelial Cells
Betamethasone
Macaca mulatta
Morphogenesis
Epidermal Growth Factor
Gases
Lung
Haplorhini
Body Weight
Fetal Development
Glycogen
Epidermal Growth Factor Receptor
Organelles
Pregnancy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys. / Edwards, L. A.; Read, L. C.; Nishio, S. J.; Weir, A. J.; Hull, W.; Barry, S.; Styne, Dennis M; Whitsett, J. A.; Tarantal, Alice F; George-Nascimento, C.; Plopper, Charles.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 274, No. 2, 1995, p. 1025-1032.

Research output: Contribution to journalArticle

@article{e0aa7398554b412ebcc3292948dbd778,
title = "Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys",
abstract = "To compare the effects of epidermal growth factor (EGF) and betamethasone on the morphogenesis of the gas exchange region and the differentiation of the alveolar type II cell during fetal lung development, fetal rhesus monkeys (78{\%} gestation) were treated in utero with EGF (5.33 mg/kg total dose), betamethasone (2.6 mg/kg total dose) or the carrier, saline (control), every other day for 7 days. EGF-treated monkeys had significantly increased body and adrenal weights. Betamethasone-treated monkeys had significantly decreased body and adrenal weights. Exogenous EGF reduced cytoplasmic glycogen and increased the cytoplasmic organelle and SP-A content within alveolar type II cells. In contrast, exogenous betamethasone did not alter alveolar type II cell cytodifferentiation. Neither EGF nor betamethasone treatment significantly altered the structure of the gas exchange region as shown by a lack of change from controls in alveolar airspace size or in the fraction of the gas exchange region that was potential airspace. We conclude that at clinically relevant doses, EGF greatly accelerates the maturation of alveolar type II cells, whereas betamethasone does not. Exogenous EGF may act directly on alveolar type II cells because these cells contain EGF receptor. Neither EGF nor betamethasone had dramatic effects on the morphogenesis of the gas exchange region.",
author = "Edwards, {L. A.} and Read, {L. C.} and Nishio, {S. J.} and Weir, {A. J.} and W. Hull and S. Barry and Styne, {Dennis M} and Whitsett, {J. A.} and Tarantal, {Alice F} and C. George-Nascimento and Charles Plopper",
year = "1995",
language = "English (US)",
volume = "274",
pages = "1025--1032",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Comparison of the distinct effects of epidermal growth factor and betamethasone on the morphogenesis of the gas exchange region and differentiation of alveolar type II cells in lungs of fetal rhesus monkeys

AU - Edwards, L. A.

AU - Read, L. C.

AU - Nishio, S. J.

AU - Weir, A. J.

AU - Hull, W.

AU - Barry, S.

AU - Styne, Dennis M

AU - Whitsett, J. A.

AU - Tarantal, Alice F

AU - George-Nascimento, C.

AU - Plopper, Charles

PY - 1995

Y1 - 1995

N2 - To compare the effects of epidermal growth factor (EGF) and betamethasone on the morphogenesis of the gas exchange region and the differentiation of the alveolar type II cell during fetal lung development, fetal rhesus monkeys (78% gestation) were treated in utero with EGF (5.33 mg/kg total dose), betamethasone (2.6 mg/kg total dose) or the carrier, saline (control), every other day for 7 days. EGF-treated monkeys had significantly increased body and adrenal weights. Betamethasone-treated monkeys had significantly decreased body and adrenal weights. Exogenous EGF reduced cytoplasmic glycogen and increased the cytoplasmic organelle and SP-A content within alveolar type II cells. In contrast, exogenous betamethasone did not alter alveolar type II cell cytodifferentiation. Neither EGF nor betamethasone treatment significantly altered the structure of the gas exchange region as shown by a lack of change from controls in alveolar airspace size or in the fraction of the gas exchange region that was potential airspace. We conclude that at clinically relevant doses, EGF greatly accelerates the maturation of alveolar type II cells, whereas betamethasone does not. Exogenous EGF may act directly on alveolar type II cells because these cells contain EGF receptor. Neither EGF nor betamethasone had dramatic effects on the morphogenesis of the gas exchange region.

AB - To compare the effects of epidermal growth factor (EGF) and betamethasone on the morphogenesis of the gas exchange region and the differentiation of the alveolar type II cell during fetal lung development, fetal rhesus monkeys (78% gestation) were treated in utero with EGF (5.33 mg/kg total dose), betamethasone (2.6 mg/kg total dose) or the carrier, saline (control), every other day for 7 days. EGF-treated monkeys had significantly increased body and adrenal weights. Betamethasone-treated monkeys had significantly decreased body and adrenal weights. Exogenous EGF reduced cytoplasmic glycogen and increased the cytoplasmic organelle and SP-A content within alveolar type II cells. In contrast, exogenous betamethasone did not alter alveolar type II cell cytodifferentiation. Neither EGF nor betamethasone treatment significantly altered the structure of the gas exchange region as shown by a lack of change from controls in alveolar airspace size or in the fraction of the gas exchange region that was potential airspace. We conclude that at clinically relevant doses, EGF greatly accelerates the maturation of alveolar type II cells, whereas betamethasone does not. Exogenous EGF may act directly on alveolar type II cells because these cells contain EGF receptor. Neither EGF nor betamethasone had dramatic effects on the morphogenesis of the gas exchange region.

UR - http://www.scopus.com/inward/record.url?scp=0029056114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029056114&partnerID=8YFLogxK

M3 - Article

VL - 274

SP - 1025

EP - 1032

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -